Related Experiment Video

Updated: Dec 1, 2025

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
09:56

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice

Published on: February 14, 2021

5.6K

The efficacy of baroreflex activation therapy for heart failure: A meta-analysis of randomized controlled trials

Guoqiang Cai1, Kai Guo1, Dongyin Zhang2

  • 1Department of Cardiology, Dianjiang Traditional Chinese Medicine Hospital, Dianjiang.

Medicine
|November 7, 2020
PubMed

Insights

Baroreflex activation therapy significantly improves quality of life and exercise capacity in heart failure patients. This therapy also reduces heart failure symptoms and hospitalizations, enhancing overall treatment efficacy.

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Trials

Background:

  • The effectiveness of baroreflex activation therapy (BAT) for heart failure (HF) remains unclear.
  • This meta-analysis evaluates BAT's impact on HF treatment efficacy.

Purpose of the Study:

  • To assess the efficacy of baroreflex activation therapy in improving outcomes for patients with heart failure.
  • To synthesize evidence from randomized controlled trials (RCTs) on BAT for heart failure.

Main Methods:

  • A systematic literature search was conducted across major databases: PubMed, EMbase, Web of Science, EBSCO, and Cochrane Library.
  • Included studies were randomized controlled trials (RCTs) investigating baroreflex activation therapy in heart failure patients.

Main Results:

  • Baroreflex activation therapy demonstrated significant improvements in quality of life (SMD = -4.61), 6-minute hall walk distance (SMD = 2.83), and New York Heart Association (NYHA) Class (SMD = -3.23).
  • The therapy also led to reductions in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (SMD = -1.24) and hospitalization duration (SMD = -1.65).
  • No significant effects were observed on left ventricular ejection fraction (LVEF) or the number of hospitalizations per year.

Conclusions:

  • Baroreflex activation therapy is an effective treatment for improving multiple clinical outcomes in heart failure patients.
  • BAT offers a promising therapeutic strategy to enhance the management and efficacy of heart failure treatment.
Abstract

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.7K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
700
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
112
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
586
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
406
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
129
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
646